TOP STORIES

• BUSINESS Novartis’ Eylea Challenger Could Reach Filing This Year for 2020 Launch
  April 8, 2019

• REGULATORY Japan’s 1st Avastin Biosimilar Could Get Listing as Early as November; Lilly’s EGFR Up for MHLW Panel Review
  April 8, 2019

• INTERVIEW With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief
  April 5, 2019

• BUSINESS Lilly Japan Nets 263 Billion Yen in 2018, Now 6th in Sales Ranking
  April 4, 2019

• BUSINESS Cefazolin Generic Shortage Raises Worries of Supply Crunch after G1 LLP Withdrawals
  April 4, 2019

• INTERVIEW Ex-Minister Tamura: 3 New Sources of Social Security Funding Needed to Stem Overreliance on Drug Price Cuts
  April 3, 2019

• COMMENTARY Building Credible, Convincing System Holds Key for Japan’s Cost-Effectiveness Assessment
  April 2, 2019

• REGULATORY MHLW Reveals Details of New Withdrawal Rules for Off-Patent Branded Drugs
  April 1, 2019

• BUSINESS Daiichi Sankyo Bags US$6.9 Billion AstraZeneca Pact for Cancer Hopeful DS-8201, Announces CEO Change
  April 1, 2019

• INTERVIEW Kyokai Kenpo Director Yoshimori: Japan Should Eventually Use Cost-Effectiveness Assessment to Set Launch Prices
  March 29, 2019

• BUSINESS Sumitomo Dainippon Carves Out Pain Program, 2025 Launch Eyed for Rare Pediatric Disease
  March 29, 2019

• REGULATORY Opdivo Up for Yet Another Re-Pricing after CEA Confirmatory Analysis, but New Price Undisclosed
  March 28, 2019

• REGULATORY National Cancer Center’s Fujiwara Named New PMDA Chief
  March 27, 2019

• BUSINESS Kymriah OK’ed, Novartis Says It’s Not Up for Outcome-Based Pricing in Japan
  March 27, 2019

• BUSINESS Novartis Snags Japan Approval for CAR-T Therapy Kymriah
  March 26, 2019

• REGULATORY Nesp Biosame Likely to Be Priced at 70% of Originator as Stopgap Measure
  March 26, 2019

• INTERVIEW With HIV Back in Hand, Gilead Heading into Second Phase in Japan Market: Pres. Hermans
  March 26, 2019

• REGULATORY PMDA Chief Kondo to Step Down after 11 Years in Charge
  March 25, 2019

• REGULATORY LDP Lawmakers Not So Positive about Reflecting Societal Values to Drug Prices; They Don’t Know How
  March 22, 2019

• BUSINESS Biogen/Eisai’s Aducanumab Fails, Dashing Hopes in Alzheimer’s Field
  March 22, 2019

ページ

• « 先頭
• ‹ Prev
• …
• 131
• 132
• 133
• 134
• 135
• 136
• 137
• 138
• 139
• …
• Next ›
• 最終 »